I
ncreased platelet production is a normal response after inflammatory insults such as trauma or infection. When patients recover after a notable inflammatory event, thrombocytosis is typically observed after approximately 1 wk, with platelet counts (PCs) leveling off to normal levels afterward. This phenomenon can be seen as a late part of the acute phase response and has been shown to be mediated by cytokines, especially interleukin-6 (1, 2). In fact, in patients with chronic diseases such as rheumatoid arthritis or inflammatory bowel disease, thrombocytosis is a marker of persistent inflammation.
On the high end of the spectrum of disease severity (e.g., sepsis or major bleeding) low PCs are correlated with disease severity. Significant initial thrombocytopenia (PC Ͻ 50⅐10 3 /mm 3 ) is known to be predictive of poor outcome in patients with sepsis or with a ruptured abdominal aortic aneurysm (3, 4) . When these patients have survived the first days after the acute event, a complex interplay of factors determines the ultimate outcome. Many parameters considered either proinflammatory or anti-inflammatory have been studied in the quest to predict and to influence outcome. Clinically useful measurement of parameters such as cytokines is difficult and is associated with considerable costs.
Although many studies have recognized the value of baseline PCs in predicting outcome, the meaning of subsequent time-dependent changes in PCs that do not excessively deviate from so-called normal values has not been studied. We have often noted that critically ill patients do not display thrombocytosis, although such a response may be expected because of the strong inflammatory stimuli that are present. To assess the clinical relevance of this phenomenon, we looked systematically at PCs after admission to the intensive care unit (ICU). In addition, leukocyte counts were also studied because leukocyte counts are frequently measured as an indicator of inflammation.
We hypothesized that a lower rise in PCs in the days after ICU admission would be associated with adverse outcome. Because the objective was to observe sequential changes in the PCs in patients who were especially at risk for a complicated course, we only studied patients who stayed at least 4 days in the ICU.
PATIENTS AND METHODS
All patients 15 yrs and older who were admitted between 1992 and 1998 to the surgical ICU of a tertiary teaching hospital for 4 days or more were studied retrospectively. Pa-Objective: To test the hypothesis that a low rate of change of platelet counts (PCs) after admission to the intensive care unit (ICU) is associated with mortality. Low PCs are known to be associated with disease severity in critically ill patients, but the relevance of time-dependent changes of PCs has not been investigated.
Design 3 ) measurements performed from ICU admission to 10 days after ICU admission were analyzed. During the patients' ICU stay, these measurements were performed daily using a Coulter Counter (Beckman Coulter, Fullerton, CA). Acute Physiology and Chronic Health Evaluation (APACHE-II) (5) scores were calculated on admission. Survival at 30 days after admission to the ICU, and hospital mortality were determined.
Statistics
Readmissions to the ICU were also included, provided they occurred more than 30 days after a previous ICU admission. Thus, a patient who was admitted previously once and died during a later readmission was counted once as a survivor and once as a nonsurvivor. When multiple determinations were made for the same patient on the same day, these values were averaged to one value for that day before daily group means were calculated. To quantify the daily increase of the PC, linear regression estimates were calculated for each individual patient as well as for patient groups. On the basis of the known bimodal change of PCs, the PC was assumed to change in a linear fashion from day 2 to day 10, as described by
For each patient, the constant a (slope) was calculated, denoted by ⌬PC/⌬t hereafter.
To assess the relation between the APACHE-II score and ⌬PC/⌬t with 30-day survival and hospital survival respectively, receiving operating characteristic (ROC) curves were constructed, with the area under the curve as a measure of discriminatory ability (6) . Data are expressed as the median with interquartile range or mean Ϯ SD. Differences were assessed using Student's t-test, and were corrected according to Bonferroni in case of multiple comparisons.
RESULTS
During the 7-yr study period, a total of 3286 different patients age 15 to 96 yrs had 3940 admissions to our surgical ICU. Of these patients, 383 died within 30 days.
When patients who were admitted for more than 4 days only were included, 1311 patients (1415 admissions) remained for further analysis. In this group, 212 patients (15% of admissions) died within 30 days after ICU admission (Table 1) . Of 277 admissions, the patients died during their hospital stay. A total of 17,364 PCs and 13,695 leukocyte counts were analyzed.
The median PC of the entire patient group dropped initially to a nadir of 113 (range, 64 -192)⅐10 3 /mm 3 on the second day after admission, and subsequently increased to 277 (range, 157-424)⅐10 3 /mm 3 after 10 days. When survivors and nonsurvivors were considered separately ( Fig. 1) , the PCs on admission showed no difference. From day 2 to day 10, the PC in survivors was significantly higher than in nonsurvivors, resulting in a PC at day 10 of 302 (range, 181-428)⅐10 3 /mm 3 and 129 (range, 62-228)⅐10 3 /mm 3 respectively. Although the mean PC differed markedly between patients groups, within all groups (i.e., trauma, vascular surgery, abdominal surgery, liver transplantation, and miscellaneous) nonsurvivors consistently had a lower rise in PC as measured by mean ⌬PC/⌬t (Fig. 2) . These differences were highly significant (p Ͻ 0.001) for all groups, with the exception of the liver transplantation group. For readmitted patients, the time-dependent changes of the PCs did not differ from patients who were first admitted.
As opposed to the PCs, overall and subgroup leukocyte counts in survivors were slightly lower compared with nonsurvivors, with values of 13. Of 1290 admissions, the daily change in PCs (⌬PC/⌬t) between day 2 and day 10 could be calculated: Thirty-day survivors had a value of 30 Ϯ 46⅐10 3 /mm 3 /day whereas nonsurvivors had a value of 6 Ϯ 28⅐10 3 /mm 3 /day (p Ͻ 0.001). With respect to 30-day survival, the area under the ROC curve was 0.743 for ⌬PC/⌬t (Fig.  3) and 0.728 for APACHE-II. The areas under the ROC curve for ⌬PC/⌬t and APACHE-II when calculated with respect to hospital survival were 0.736 and 0.708, respectively. 
DISCUSSION
The aim of this study was to analyze the time response of the PCs in relation to outcome in critically ill patients. In patients who recover uneventfully from an inflammatory insult, the PC displays a bimodal response with an initial decrease below baseline values for the first days, followed by an increase above the normal range after 1 wk. In the current study, the surviving trauma patients clearly showed such a response (see Fig. 2A ). Trauma patients sustained their injury and subsequent definitive surgery in most cases within 24 hrs before ICU admission. Combined with the fact that nearly all of these patients were previously healthy and relatively young, as opposed to most patients in the other patient groups, this may explain why the bimodal time course of PCs was most marked in trauma patients.
In the other patient groups, lower overall PCs were observed, especially in patients who underwent liver transplantation (see Fig. 2D ). In this latter group, splenomegaly is a major determinant of low PC. Nevertheless, in all patients groups we saw the same diverging pattern between those who eventually died and those who survived. PCs in survivors were twice the value of nonsurvivors at day 10. When the rate of change of ⌬PC/⌬t from day 2 onward was examined, this value was fivefold higher in survivors compared with nonsurvivors. If the change in PC is considered from day 0 onward instead of from day 2 onward, the difference between survivors and nonsurvivors would be even more striking. But the reason for calculating ⌬PC/⌬t from day 2 onward, and not from day 0 onward, was to fit appropriately the bimodal time course of PCs.
The constancy and reproducibility of the PC in normal individuals has already been established by Brecher (7) ), in any normal individual the PC varies only by approximately 60⅐10 3 /mm 3 . The use of ⌬PC/⌬t removes baseline interindividual differences. That ⌬PC/⌬t shows greater differences between survivors and nonsurvivors than the PC itself underscores that Brecher's (7) observation of normal individuals is very relevant in patients as well.
The relation between a blunted rise in PCs and outcome is not restricted to surgical ICU patients, as shown in 206 patients at a medical ICU (9) . In that study, which excluded patients with entities known to affect PCs directly (i.e., acquired immune deficiency syndrome, leukemia, chemotherapy, immune thrombocytopenia, and hemolytic uremic syndrome), survivors also showed significantly higher PCs from ICU day 3 onward. In a recent study on the international EURICUS-II database compiling data from 1,636 patients from 61 centers with both medical and surgical ICU patients, we also found that ⌬PC/⌬t dis- criminates survivors from nonsurvivors (10) .
That the PC can be a good parameter to monitor critically ill patients is also reflected in the new emphasis on this parameter in recently introduced scoring systems for critically ill patients. The sequential organ failure assessment score (11) uses the PC and not the leukocyte count as one of its six components. Likewise, the multiorgan dysfunction score (12) uses the PC and not the leukocyte count as one of seven components. The older and still widely used APACHE-II uses the leukocyte count, but not the PC. It is obviously not our intention to promote ⌬PC/⌬t as yet another prognostic scoring system, especially because one parameter can never be the foundation of a prognostic score for such complex patients as there are in the ICU. But the fact that ⌬PC/⌬t is as good as APACHE-II in predicting mortality is remarkable, and makes it a candidate component of scoring systems. It should not be difficult to verify our findings on the existing databases that are the foundation of the previously mentioned scores (11, 12) . Because these scores already use PC as a component, they could be reanalyzed with the inclusion of ⌬PC/⌬t.
The blunted rise of the PCs in the nonsurvivors must be the result of consumption that is relatively higher than production. Although it is difficult to discriminate between decreased platelet synthesis and increased consumption, it is probable that especially increased consumption of platelets is present. If bone marrow insufficiency or regulatory abnormalities are assumed to cause decreased platelet synthesis, this phenomenon is not reflected by decreased leukocyte counts in our patient set, because nonsurvivors even had higher leukocyte counts than survivors.
Consumption of platelets can be caused by disseminated intravascular coagulation and sequestration in organs. Disseminated intravascular coagulation is frequently present in critically ill patients: It was found in 29 of 35 ICU patients with systemic inflammatory response syndrome (13) . In the acute respiratory distress syndrome, the trapping of platelets in the lung has long been known (14) . Sigurdsson Indium-labeled platelets at the bedside. Patients with poor outcomes showed trapping of platelets in the gut as well as in the lung, liver, and spleen. This phenomenon was observed 1 to 4 days before clinical sepsis or multiorgan failure. After liver transplantation, approximately 50% of the circulating platelets are sequestrated in the transplanted liver immediately after reperfusion (16) . It has been shown that platelet sequestration in the liver graft is associated with increased reperfusion damage. Persistent thrombocytopenia after transplantation was found to be associated with decreased survival (17) , which is in agreement with the observations in the current study.
Naturally, the question arises if interventions aimed at preventing platelet consumption would affect outcome. Again, reanalysis of existing data sets of intervention studies with regard to ⌬PC/⌬t would be of great interest. Such analyses could answer if ⌬PC/⌬t is related to outcome, and if the intervention affected ⌬PC/⌬t.
Thus, in patients who are not critically ill, increased PCs often indicate ongoing inflammation and disease. But in critically ill patients, the opposite is the case because a blunted rise in PCs (i.e., a low ⌬PC/⌬t) has an unfavorable prognosis. The presence of a "normal" PC after ICU admission should not be interpreted automatically as desirable. Therefore, the PC, determined routinely at low cost, should not only be used to detect thrombocytopenia or thrombocytosis, it should also be used to follow actively its timedependent changes. 
